The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
|Articles|February 23, 2016
FDA Nod for Bracco’s Barium-Sulfate Oral Suspension
Author(s)Diagnostic Imaging Staff
FDA approves Bracco’s READI-CAT 2 and READI-CAT 2 SMOOTHIE for use in abdominal CT.
Advertisement
The U.S. Food and Drug Administration has approved a New Drug Application for READI-CAT 2 and READI-CAT 2 SMOOTHIE, barium sulfate oral suspensions for use in CT.
READI-CAT 2 and READI-CAT 2 SMOOTHIE, products of Bracco Imaging, a subsidiary of Bracco Diagnostics, are used in CT of the abdomen to delineate the gastrointestinal tract in adult and pediatric patients, a release said.
This approval is the second regulatory approval of a barium-based contrast agent in the U.S., and the first for use in modern CT imaging, Bracco’s release said.
READI-CAT 2 is supplied in 450 mL bottles; READI-CAT 2 SMOOTHIES, also in 450 mL bottles, are available for use by adult and pediatric patients in berry, banana, creamy vanilla and mochaccino flavors.
Advertisement
Related to this article
Catch up on the top radiology content of the past week.
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA
4
Can the Kaiser Score with Breast MRI Improve Clarity for BI-RADS 0 and 4 Assessments on Mammography and Ultrasound?
5